Syndax Pharmaceuticals (SNDX) EBT: 2015-2024
Historic EBT for Syndax Pharmaceuticals (SNDX) over the last 10 years, with Dec 2024 value amounting to -$318.5 million.
- Syndax Pharmaceuticals' EBT fell 39.81% to -$19.9 million in Q4 2020 from the same period last year, while for Dec 2020 it was -$71.4 million, marking a year-over-year decrease of 24.13%. This contributed to the annual value of -$318.5 million for FY2024, which is 52.40% down from last year.
- Latest data reveals that Syndax Pharmaceuticals reported EBT of -$318.5 million as of FY2024, which was down 52.40% from -$209.0 million recorded in FY2023.
- Syndax Pharmaceuticals' EBT's 5-year high stood at $24.7 million during FY2021, with a 5-year trough of -$318.5 million in FY2024.
- Over the past 3 years, Syndax Pharmaceuticals' median EBT value was -$209.0 million (recorded in 2023), while the average stood at -$225.5 million.
- As far as peak fluctuations go, Syndax Pharmaceuticals' EBT surged by 133.90% in 2021, and later slumped by 702.74% in 2022.
- Yearly analysis of 5 years shows Syndax Pharmaceuticals' EBT stood at -$72.9 million in 2020, then surged by 133.90% to $24.7 million in 2021, then crashed by 702.74% to -$149.0 million in 2022, then crashed by 40.25% to -$209.0 million in 2023, then crashed by 52.40% to -$318.5 million in 2024.